Veterinary Eye Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Diagnosis, Treatment), By Animal Type (Canine, Feline, Equine, Bovine, Other), By Route of Administration (Oral, Topical, Injectable), By Indication (Eyelid Abnormalities, Cataract, Glaucoma, Retinal Complications, Uveitis, Conjunctivitis, Corneal Complications, Others), By Sales Channel (Veterinary Hospitals & Clinics, Pet Specialty Stores, E-Commerce, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 5.20 Billion
CAGR (2026-2031)	6.01%
Fastest Growing Segment	Treatment
Largest Market	North America
Market Size (2031)	USD 7.38 Billion

Market Overview

The Global Veterinary Eye Care Market will grow from USD 5.20 Billion in 2025 to USD 7.38 Billion by 2031 at a 6.01% CAGR. Veterinary eye care encompasses the diagnostic, pharmaceutical, and surgical modalities utilized to manage ocular diseases in animals. The primary drivers supporting market growth include the rising prevalence of ophthalmic conditions alongside a measurable increase in pet ownership that expands the potential patient pool. According to the American Veterinary Medical Association, in 2024, the population of pet dogs in the United States reached an estimated 89.7 million. This expanding demographic directly correlates with heightened demand for services as owners increasingly prioritize animal health.

The sector encounters a significant challenge regarding the high costs associated with specialized ophthalmic procedures and a global shortage of qualified specialists. These financial and logistical barriers can limit access to necessary treatments for many pet owners and potentially impede the broader expansion of the market into emerging economies.

Key Market Drivers

Increasing consumer expenditure on specialized animal healthcare serves as a fundamental catalyst for the growth of the veterinary eye care sector. As pet owners increasingly characterize their companions as integral family members, their propensity to fund advanced medical interventions, including ophthalmology, has surged significantly. This economic behavior extends beyond basic preventative measures to encompass sophisticated treatments for complex conditions such as cataracts, glaucoma, and retinal degeneration. According to the American Pet Products Association, March 2024, in the 'State of the Industry' data release, total pet industry expenditures in the United States reached $147.4 billion in 2023. This substantial financial outlay indicates a robust economic capacity for owners to afford referral-based veterinary services, directly benefiting specialty practices focused on maintaining and restoring animal vision.

The expansion of pet insurance coverage for ophthalmic treatments further accelerates the adoption of these specialized services by mitigating associated financial barriers. Complex ocular surgeries are often capital-intensive, yet the rising penetration of comprehensive insurance policies allows for broader access to these necessary procedures. According to Forbes Advisor, in January 2024, the average cost of cataract surgery for dogs ranges between $2,700 and $4,000 per eye, highlighting the significant investment required for restorative vision care. Consequently, the insurance sector has expanded rapidly to address these potential liabilities. According to the North American Pet Health Insurance Association, May 2024, in the 'State of the Industry Report 2024', the total premium volume for pet insurance in the United States increased to $3.9 billion, signaling a shift toward financial preparedness that sustains the demand for high-value veterinary eye care.

Download Free Sample Report

Key Market Challenges

The global shortage of qualified veterinary specialists represents a critical bottleneck effectively restraining the expansion of the eye care market. Ocular diseases in animals often demand sophisticated surgical interventions and long-term management plans that general practitioners are rarely equipped to provide. When the supply of board-certified veterinary ophthalmologists fails to keep pace with the increasing population of pets, the immediate result is a severe limitation on the number of advanced procedures, such as phacoemulsification or corneal grafts, that can be performed annually. This scarcity creates long wait times and forces price increases that inevitably price out a segment of the consumer base, thereby capping the market’s total realizable revenue.

This workforce deficit is structural and directly restricts the industry's capacity to scale operations, particularly in underserved regions. The pipeline for new specialists is currently insufficient to meet the surging demand for services. According to the American Association of Veterinary Medical Colleges, in 2024, internal data indicated a 10% shortage of veterinary faculty, a deficit that directly impedes the academic sector's ability to train and graduate the next generation of specialists. Without a robust influx of new professionals to alleviate this pressure, the market struggles to broaden its service reach, leaving significant potential revenue in both developed and emerging economies unrealized.

Key Market Trends

The Integration of Artificial Intelligence for Ocular Disease Detection is rapidly fundamentally altering diagnostic precision and workflow efficiency within veterinary practices. This trend involves the deployment of machine learning algorithms capable of analyzing complex retinal images and corneal scans to identify pathologies such as glaucoma, cataracts, and progressive retinal atrophy with accuracy comparable to human specialists. By automating the assessment of ocular structures, these tools reduce diagnostic errors and allow general practitioners to triage eye conditions more effectively before referring to specialists. The momentum of this technological shift is evident in professional adoption rates; according to the North American Veterinary Community, August 2024, in the 'Veterinary Innovation Summit' report, approximately 39.2% of surveyed veterinary industry experts now utilize AI tools in their daily work, signaling a robust environment for the continued penetration of AI-driven ophthalmic diagnostics.

Simultaneously, the market is witnessing a critical Advancement in Sustained-Release Ocular Therapeutic Delivery designed to overcome the significant challenge of owner compliance in managing chronic eye conditions. Conventional treatment often requires frequent administration of eye drops, which is difficult for pet owners to maintain consistently, leading to suboptimal clinical outcomes for lifelong diseases like keratoconjunctivitis sicca (dry eye). New bio-engineered hydrogels and episcleral implants allow for the continuous, controlled release of medication over weeks or months, ensuring therapeutic efficacy. This innovation is particularly vital given the high susceptibility of certain breeds to chronic ocular surface diseases; according to the Royal Veterinary College, January 2024, in the 'VetCompass' study, English Cocker Spaniels exhibit a 7.6 times higher risk of developing keratoconjunctivitis sicca compared to other breeds, underscoring the urgent market need for these advanced, long-acting therapeutic solutions.

Segmental Insights

The Treatment segment represents the fastest-growing category within the Global Veterinary Eye Care Market, primarily driven by the increasing prevalence of ophthalmic disorders such as cataracts and glaucoma in companion animals. This expansion is supported by the rising approval of novel therapeutic drugs by regulatory authorities like the U.S. Food and Drug Administration, which enhances the accessibility of effective medical interventions. As pet owners increasingly prioritize ocular health, the demand for pharmaceuticals to manage chronic and acute eye conditions continues to rise, ensuring the sustained development of this segment.

Regional Insights

North America maintains a dominant position in the global veterinary eye care market, driven by a well-established animal healthcare infrastructure and high levels of pet ownership. The region benefits from the strong presence of major pharmaceutical companies and consistent expenditure on veterinary services. Additionally, the increasing diagnosis of ophthalmic conditions in companion animals accelerates the demand for therapeutic solutions. This expansion is supported by structured regulatory pathways provided by the U.S. Food and Drug Administration, which streamline the approval process for new veterinary ophthalmic medications and devices.

Recent Developments

• In February 2025, Hikma Pharmaceuticals USA Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Animal Drug Application (ANADA) for Tulathromycin Injection. This generic injectable solution was indicated for the treatment of multiple respiratory and ocular conditions in livestock, specifically including the treatment of infectious bovine keratoconjunctivitis (IBK), commonly known as pinkeye, in beef and non-lactating dairy cattle. The approval of this generic alternative provided veterinarians and livestock producers with a new, cost-effective therapeutic option for managing this highly contagious bacterial eye disease that significantly impacts cattle health and productivity.
• In November 2024, Dômes Pharma Group strengthened its position in the North American veterinary ophthalmology market by officially renaming its U.S. subsidiary, SentrX Animal Care, to Dômes Pharma, Inc. Alongside this corporate rebranding, the company acquired the NeoPolyBac veterinary label from Akorn Pharmaceuticals. This acquisition added a triple antibiotic ophthalmic ointment, widely used for treating bacterial eye infections in animals, to their therapeutic portfolio. These strategic moves were intended to unify the company’s global brand identity and enhance its capacity to deliver a comprehensive range of ophthalmic solutions to veterinarians across the United States.
• In July 2024, VetRxDirect, a pet pharmacy service, established a partnership with Epicur Pharma to expand its portfolio of veterinary medications. Through this collaboration, VetRxDirect began offering Epicur’s range of 503B manufactured ophthalmic drugs directly to veterinary practices and pet owners. This development provided access to high-quality, standardized ophthalmic treatments, including cyclosporine and tacrolimus formulations, which are verified for stability and sterility. The initiative aimed to address the need for reliable, commercially available compounded medications for treating complex ocular conditions in companion animals, ensuring compliance with FDA standards for outsourced compounded drugs.
• In April 2024, Millpledge Veterinary announced the launch of a novel ocular lubricant named Oculeze, designed to support the eye health of various animal species including dogs, cats, horses, and rabbits. This new addition to their veterinary portfolio was formulated to assist in the management of conditions that require additional moisture or lubrication on the ocular surface. The product featured a pH-neutral composition with natural active ingredients such as glycerin, aloe vera, chamomile, and propolis extract. The inclusion of propolis was highlighted for its potential to support corneal health through the modulation of the tear film and reduction of inflammation.

Key Market Players

• Bausch + Lomb Corporation
• Akorn Operating Company LLC
• Boehringer Ingelheim International GmbH
• I-MED Pharma Inc.
• Innovacyn, Inc.
• Miracle Pet
• Compana Pet Brands LLC
• Zoetis Services LLC
• Epicur Pharma
• Icare Finland Oy

By Type	By Animal Type	By Route of Administration	By Indication	By Sales Channel	By Region
Diagnosis Treatment	Canine Feline Equine Bovine Other	Oral Topical Injectable	Eyelid Abnormalities Cataract Glaucoma Retinal Complications Uveitis Conjunctivitis Corneal Complications Others	Veterinary Hospitals & Clinics Pet Specialty Stores E-Commerce Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Eye Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Eye Care Market, By Type:

• Diagnosis
• Treatment

• Veterinary Eye Care Market, By Animal Type:

• Canine
• Feline
• Equine
• Bovine
• Other

• Veterinary Eye Care Market, By Route of Administration:

• Oral
• Topical
• Injectable

• Veterinary Eye Care Market, By Indication:

• Eyelid Abnormalities
• Cataract
• Glaucoma
• Retinal Complications
• Uveitis
• Conjunctivitis
• Corneal Complications
• Others

• Veterinary Eye Care Market, By Sales Channel:

• Veterinary Hospitals & Clinics
• Pet Specialty Stores
• E-Commerce
• Others

• Veterinary Eye Care Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE